GlassScriptPhysician profile
Esteban Cedillo-Couvert
NPI 1407023476
$1,716.64
in general payments reported to CMS, 2019-2025
15 companies · $19.73 in 2025
The $19.73 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $160 · 2021: $459 · 2022: $239 · 2024: $242 · 2025: $19.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $334.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $234.65 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $217.95 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Akebia Therapeutics INC | $124.99 | 2022 | |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Novo Nordisk INC | $117.12 | 2024 | |
| Mallinckrodt Hospital Products INC. | $112.47 | 2021 | |
| Horizon Therapeutics Plc | $103.37 | 2021 | |
| Baxter Healthcare | $86.34 | 2019 | |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Glaxosmithkline, LLC. | $19.73 | 2025 | Arexvy, Shingrix |
| Fresenius USA Marketing, INC. | $19.70 | 2020 | |
| Vifor Pharma, INC. | $15.89 | 2019 | |
| Daiichi Sankyo INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esteban Cedillo-Couvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.